Orexo AB (publ)

Stockholm Stock Exchange ORX.ST

Orexo AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2023: -18.93%

Orexo AB (publ) Return on Capital Employed (ROCE) is -18.93% for the year ending December 31, 2023, a 3.99% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Orexo AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -19.72%, a 9.31% change year over year.
Orexo AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -21.75%, a -521.48% change year over year.
Orexo AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -3.50%, a -114.71% change year over year.
Orexo AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 23.79%, a 113.49% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Stockholm Stock Exchange: ORX.ST

Orexo AB (publ)

CEO	Mr. Nikolaj Sorensen
IPO Date	Nov. 9, 2005
Location	Sweden
Headquarters	P.O. Box 303
Employees	113
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Mental Health Personal Care

Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Key trends

Past 5 years